Your session is about to expire
← Back to Search
Gain-framed messages for Cervical Cancer
N/A
Waitlist Available
Led By Xiaoli Nan
Research Sponsored by University of Maryland, College Park
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
18 years or older
Self-identify as African American
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline posttest (test was approximately 5 minutes to complete)
Awards & highlights
Study Summary
A Message Framing Intervention for Increasing Parental Acceptance of Human Papillomavirus Vaccination
Eligible Conditions
- Cervical Cancer
- Anal Cancer
- Penile Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline posttest (test was approximately 5 minutes to complete)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline posttest (test was approximately 5 minutes to complete)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Attitudes
Intention to Vaccinate Free of Cost
Secondary outcome measures
Intention to Vaccinate With Cost
Side effects data
From 2012 Phase 3 trial • 6104 Patients • NCT0134659227%
Injection site pain
25%
Pyrexia
14%
Upper respiratory tract infection
14%
Decreased appetite
14%
Diarrhea
10%
Injection site erythema
9%
Nasopharyngitis
9%
Irritability postvaccinal
9%
Headache
8%
Vomiting
8%
Injection site induration
7%
Hypersomnia
7%
Myalgia
7%
Injection site swelling
7%
Fatigue
6%
Crying
6%
Injection site hemorrhage
4%
Gastroenteritis
1%
Pneumonia
1%
Animal Bite
100%
80%
60%
40%
20%
0%
Study treatment Arm
ATIV (6 to <72 Months)
TIV (6 to <72 Months)
Comparator TIV (6 to <72 Months)
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Loss-framed messagesExperimental Treatment1 Intervention
Participants in this arm receive loss-framed HPV vaccination messages.
Group II: Gain-framed messagesExperimental Treatment1 Intervention
Participants in this arm receive gain-framed HPV vaccination messages.
Group III: Control messagesActive Control1 Intervention
Participants in this arm receive non-framed HPV vaccination messages.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HPV vaccination messages
2021
N/A
~1170
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
13,627 Previous Clinical Trials
40,926,171 Total Patients Enrolled
University of Maryland, College ParkLead Sponsor
154 Previous Clinical Trials
44,315 Total Patients Enrolled
Xiaoli NanPrincipal InvestigatorUniversity of Maryland, College Park
1 Previous Clinical Trials
456 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger